Login
$PSNL
$14.59 -$0.21 (1.42%) After hours

$PSNL 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

Reports Q3 clinical test volume of 13,157, clinical revenue of $4.4 million and overall revenue of $25.6 million

06 Oct 2026 8-K: Other Events

As previously disclosed, on July 20, 2026, Personalis, Inc., a Delaware corporation (“Personalis” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Tempus AI, Inc., a Nevada corporation (“Tempu...

20 Aug 2026 8-K: Other Events

On August 20, 2026, Personalis, Inc. received a new task order under its contract with the U.S. Department of Veterans Affairs (VA) for the VA's Million Veteran Program (VA MVP). The new task order is effective on September 30, 2026 and ...

04 Aug 2026 8-K: Results of Operations and Financial Condition

Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2

20 Jul 2026 8-K: Entry into a Material Definitive Agreement

This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of July 20, 2026, is by and among Tempus AI, Inc., a Nevada corporation (“Parent”), Aviary Development, Inc., a Delaware corporation and a direct, wholly-owned Subsidiary of ...

20 Jul 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

20 May 2026 8-K: Other Events

On May19, 2026, the Centers for Medicare & Medicaid Services Molecular Diagnostics Program expanded Medicare coverage for Personalis, Inc.’s ultrasensitive NeXT Personal® test to include monitoring treatment response to neoadjuvant thera...

13 May 2026 8-K: Submission of Matters to a Vote of Security Holders

On May 12, 2026, Personalis, Inc. (the “Company”) virtually held its 2026 annual meeting of stockholders (the “Annual Meeting”). Present at the Annual Meeting virtually or by proxy were the holders of 91,869,300 shares of common stock of...

13 May 2026 8-K: Other Events

On May12, 2026, the Centers for Medicare & Medicaid Services Molecular Diagnostics Program expanded Medicare coverage for our ultrasensitive NeXT Personal® test to include immunotherapy monitoring for patients with late-stage solid tumors.

07 May 2026 8-K: Results of Operations and Financial Condition

Personalis Reports First Quarter Results and Recent Highlights

17 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.

26 Feb 2026 8-K: Results of Operations and Financial Condition

Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

08 Jan 2026 8-K: Results of Operations and Financial Condition

Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

28 Nov 2025 8-K: Other Events

We have acted as counsel to Personalis, Inc., a Delaware corporation (the “Company”), in connection with the offering by the Company of shares of its common stock, par value $0.0001 per share, having an aggregate offering price of up to ...

25 Nov 2025 8-K: Other Events

On November 24, 2025, the Centers for Medicare & Medicaid Services Molecular Diagnostics Program revised its reimbursement rate determination for Medicare coverage for our ultrasensitive NeXT Personal® test for post-treatment surveillanc...

10 Nov 2025 8-K: Other Events

On November 7, 2025, our ultrasensitive NeXT Personal® test received Medicare coverage for post-treatment surveillance of cancer recurrence in patients with stage II and III breast cancer. This coverage determination from the Centers for...

04 Nov 2025 8-K: Results of Operations and Financial Condition

Company Advances "Win-in-MRD" Strategy with Compelling Clinical Trial Data and Increasing Physician Adoption of NeXT Personal® Platform

22 Aug 2025 8-K: Other Events

On August 19, 2025, Personalis, Inc. received a new task order under its contract with the U.S. Department of Veterans Affairs (VA) for the VA's Million Veteran Program (VA MVP). The new task order is effective on September 30, 2025 and ...

05 Aug 2025 8-K: Results of Operations and Financial Condition

Strong Q2 Clinical Momentum with 59% Sequential Growth in Test Volume

09 Jul 2025 8-K: Entry into a Material Definitive Agreement

On July 8, 2025, Personalis, Inc. (the “Company”) and Tempus AI, Inc. (“Tempus”) entered into Amendment No. 4 (the “Amendment”) to the Commercialization and Reference Laboratory Agreement, dated November 25, 2023, by and between the Comp...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support